Table 4.
Liposomes applied to the treatment of systemic infections.
| Formulation | Active principle | Composition | Therapeutic target | Route of administration | Reference |
|---|---|---|---|---|---|
| Unmodified liposomes, Phospholipid-PEG modified liposomes, Pluronic modified liposomes and Chitosan coated liposomes | synthetic toll like receptor-4 agonist, CRX-601 | Unmodified liposomes : 2 mg/mL CRX- 601, 10 mg/mL cholesterol, and 40 mg/mL of phospholipid Phospholipid-PEG modified liposomes: 1.5 and 25 mol% PEPEG2K or PE-PEG5K Pluronic modified liposomes: 5, 15 and 25 mol% of Pluronics L64, F68 and F127 Chitosan coated liposomes: chitosan glycol trimethyl ammonium iodide with CRX-601 liposomes at varying ratios |
Influenza virus | sublingual | Hardeep et al., 2017 |
| CCL and CCCL | Colistin |
CCL: 8 mg colistina, 1 mL distilled water (ddH2O), 200 mg Lipoid ®S75 and Chol-SO4 CCCL: 8.0 mg colistina, outer layer: DSPC, DOPE, PEG-PE and CH (3:3:2:4 or 4:3:1:4) inner layer: DODAP and DOPE (9:1) |
E. coli | Intravenous | Li et al., 2016 |
| Fluorescently labelled liposomes and Liposomal amikacin | Amikacin | 0.2 wt% of [diI(3), 2 g of lipid 2:1 (DPPC and cholesterol, respectively) | P. aeruginosa | Inhaled | Meers et al., 2008 |
| TFL Lipossome | dinitroaniline (TFL-A) | lipidic components: PC F1 and F2, DOPG, DOPC and dppg (10 µmol/ mL) and TFL (335–450 µg/mL) | Leishmania infantum | intraperitoneal | Carvalheiro et al., 2015 |
| nSSL-BMS | glucocorticosteroid, β-methasone hemisuccinate | HSPC/cholesterol/PEG-DSPE at a mole ratio of 55 : 40 : 5 hydrated with 250 mM calcium acetate | Plasmodium berghei | Intravenous | Guo et al., 2014 |
| nSSL- MPS and nSSL - BMS | glucocorticoid prodrugs methylprednisolone hemisuccinate and β-methasone hemisuccinate | HSPC/cholesterol/PEG-DSPE at a mole ratio of 55 : 40 | Plasmodium berghei | Intravenous | Waknine-Grinberg et al., 2013 |
| DCP Vancomycin | Vancomycin | DSPC, DCP and cholesterol in a molar ratio of 7:2:1 (71.5 mg of DSPC, 14.1 mg of DCP and 5 mg of cholesterol) | Staphylococcus aureus (MRSA) | Intravenous | Sande et al., 2012 |
| WGA-Lip PEG-Lip |
Clarithromycin | PC, cholesterol, DC-Chol and clarithromycin | Staphylococcus aureus (MRSA) | Intravenous | Meng et al., 2016 |
| LVCZ | Voriconazole | PC, cholesterol, VCZ, and alpha-tocopherol, (1.0:0.5:0.11:0.05 M ratio) | Candida albicans and Aspergillus sp. | Intravenous | Veloso et al., 2018 |
1,2-distearoyl-snglycero-3-phosphoethanolamine sodium salt (PE-PEG2K) and N1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, sodium salt (PE-PEG5K), sodium cholesteryl sulphate (Chol-SO4-) distilled water (ddH2O), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2- distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy(polyethylene glycol)-2000] (mPEG-PE), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and cholesterol (CH), 1,10 -dioctadecyl-3,3,30,30 -tetramethylindocarbocyanine perchlorate [diI(3), egg phosphatidylcholine (PC F1), addition of PG promotes good incorporation to PC (PC F2), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylglycerol (DPPG), Hydrogenated soybean phosphatidylcholine (HSPC), distearoyl-snglycero-3-phospho-ethanolamine sodium salt (DSPE), Dicethylphosphate (DCP), Cholesteryl 3β-N-di-methyl-amino-ethyl-car bamate hydrochloride (DC-Chol) and soybean phosphatidylcholine (PC).